Patients with plaque psoriasis treated with Johnson & Johnson’s oral IL-23 inhibitor JNJ-2113 have been shown to maintain skin clearance for up to a year, pointing to
Sanofi is paying $175 million upfront to claim a share of an experimental vaccine developed by Johnson & Johnson’s pharma unit Janssen that aims to tackle a major caus
Idorsia has lost Johnson & Johnson's Janssen Biotech unit as the partner for its aprocitentan candidate for resistant hypertension, following a likely delay in the FDA
Johnson & Johnson has been given FDA approval for Akeega, a combination tablet for first-line treatment of adults with BRCA-positive metastatic castration-resistant pr
Understanding complex scientific studies is often a challenge for patients as well as healthcare professionals, but one that may become easier thanks to artificial intelli
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.